Subscribe
shutterstock_1137688736_shidlovski
Shidlovski / Shutterstock.com
8 February 2021EuropeJackie Mulryne

Second medical use: a regulatory perspective

As compound patents and regulatory data protection for medicinal products expire, pharmaceutical companies increasingly look to develop new uses for their products. This strategy usually involves filing second medical use patents to protect the invention and research investment.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
LSPN Europe: Navigating the EPO and lessons from the UPC frontline